Member Info for tuan6

Sharte price depen on what company offer and what they can delivery on target. If a company make money and pay dividend so its share price never down 90% over its life time. If bad news and bas management so expecting so very bad on return. Blame for single poster for share lose its value is not correct way insteard looking at what company offer to market.

As fast as they spend until the last of 700k there will be a place shares for news low price. it is now now but in two month time very quick and two month time for cancer trial is too short for find out if it good or bad.

Today it is 168 p so if it can go 560 p why dont peoples buy it? Something to must dream but it seem not come true either.

Just two day ago a lot peoples bouhgt this share at 340p now it is too cheap. nothing change but good to buy more.

As standards there is no holding RNS or TR1 RNS show that nobody tick this share until they show it work. As long as place share it had been sold forward so that is why it cvant be trusted when they state someone in US buy in but none. How long 700k last?

only three months they place three time with typical old money is 1.5 p but now it is 0.4 p that show scare lost value so much and CEO didnt buy single share. If they so confident that work they need take share option for better in future but none of that , CEO still like money a lot so complete new picture on how this work.

Yes they are working hard that is true but just keep working and keep place news shares so market will pour more money ultil it work

Place share have been forward sold befoce it RNS so they have better price , ow only left shareholders are selling at lost as they run away from this share. @8 days results cant bring this share up as nothing really bring big pharmacy come in until they know it better.

It is out of blue moon if you dream after 28 days this share worth billions as it never come true. If it good it may be higher but not a lot and then trial keep going 6 months time so how can they have fund on place to keep working?

I bought this share on 2018 at 2.5p with full of hope on Cancer treatment . Yes I hight like all researchs for all to see how this company work and this state they need more money than ever before.

Share price only stop decline when a big pharma come in or they must sell part of company to have fund to keep working. Otherwise share will come back penny soonrr or later. It typical cost 1 billion for research cancer so how company can afford to have that fund if they have nothing at moment.

Phase 1 trial at least 1 year to have data to find out safety first and effectively so at moment thete is not enough money to go untill someone see their work first before they give out thier money.

A promise big US investors not to buy penny shares turn now treating shareholder as funny as there is no big investors only small one that all . .pl

Place share will come after towontjs time so plenty of time until that .

Trading Update

The Board announced on 14 January 2025 the launch of a Strategic Review and noted that it had a number of significant near-term opportunities (the "Material Opportunities") with a potential contract value for the financial year ending 31 March 2026 of approximately £15 million. It further noted significant milestones for these Material Opportunities were scheduled for the fourth quarter of the financial year ending 31 March 2025.

Whilst all of these Material Opportunities remain intact, recent discussions with associated customers have confirmed that they will predominantly not start before the next financial year and therefore that their impact on the current financial year ending 31 March 2025 will be minimal. Accordingly, the Board now expects that Group revenue for the current financial year ending 31 March 2025 will be in the range of £5 to £6 million compared with the previous guidance of £9 million.

The Board continues to anticipate that the cash resources of the Group will last until approximately the end of May 2025.

the next step is what price for share place? if they discount 70% so if you want to buy this share just wait litle time very soon they need place share for keep the light.

I am really hope they can make it work to save cancer patient that greate if it work . Nobody in here are againt that greate news . nodoby in here again that news too.

Market will show price of share worth whereever you want to see. This share today worth 0.4p compare last 2 months 1.2p so it lose around over 50% Somethign is not right so market bring its down that is an answer. If it worth billion and now next couble weeks so why All of big pharmacy companies dont come to ask them for ?the fact none of them come to Hemo as they got nothign for sell yes.

CAR-T, CDX and CBR , CDX, HUphe . what is main point when company dont have resource but research a lot big cell tech at one? Typical research cancer around 1 billion so they need something 5 billions do to those researchs , In the end all of that nothing more than place sharte to getting money as none of them delivered any useful .

Company with many companys the same on cancer research they dont have as many as Hemo but they have at least public some reults so bring more confidence to its shareholders. 6 years until now what happen to CDX, Hu Phe1 result? They just drump it as it is funished

As everybody like if it work as it safe life, That is great news for cancer patients. nobody are againt that point. The way peoples complaint about how its financial fund work as the way they do destroyed all value and belift from investors . That is what peoples are talking in here.

That is thew way company work and what they can work on as they promise and what they delivered until today. Nothing . If they said they dip in research with Covid then drump it on the way how do you thing they spent your money for what?

15 Jun 2020 07:00

RNS Number : 8905P

Hemogenyx Pharmaceuticals PLC

15 June 2020

Hemogenyx Pharmaceuticals plc

(the "Company")

COVID-19 Project Update

Hemogenyx Pharmaceutical plc is pleased to announce progress in relation to its COVID-19 program.

On 24 June 2019, the Company announced the completion of the development of its second generation Advanced peripheral blood Hematopoietic Chimera ("ApbHC") or advanced humanised mice which offer several advantages over existing humanised mouse models. In particular, ApbHC do not develop Graft versus Host Disease ("GvHD"), which can compromise the utility of other similar types of humanised mice. The Directors considered that AbpHC, in addition to their use for disease modelling and drug testing, could potentially be used as a tool for the rapid discovery of human antibodies against human specific viral pathogens.

Subsequent work through the Company's subsidiary, Immugenyx, LLC ("Immugenyx"), had produced positive preliminary results prior to the emergence of COVID-19. In light of the emergence of the current major pandemic, work has been refocussed on COVID-19 with the aim of producing an effective treatment for those infected with the virus, and Immugenyx is currently taking the necessary steps to take this forward effectively. The work involves transplanting cells from blood samples from patients who have already recovered from COVID-19 into the ApbHC. This process will allow the Company's scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of COVID-19 sufferers.

In view of the continuing international spread of the disease and the propensity for coronaviruses to mutate and produce new strains, the Company's technology, in combination with the use of its humanised mice, should also form the basis for the treatment of future viral outbreaks.

Meanwhile, as announced on 22 April 2020, the Company has progressed its work, currently using blood samples from convalescent patients, to attempt to establish why some individuals who are infected with SARS-CoV-2 are asymptomatic, some exhibit mild symptoms, and some become very sick. This work will be of value in developing new forms of treatment, and especially in managing infection risk and assisting individuals better to establish their real risk of getting sick.

The additional funds raised recently have enabled the Company to take these and other developments forward significantly and at a faster pace.

That is promise from company how research and treament Covid19 and until now 5 years later they public something call CRB nobody know how it work.

All you blame for troll and shorter but company deliver nothing and just drump a rns to getting money first is the main point it down value. That is what it value in market as they got nothing for sell yes.

Keeping it as market will value what it worth.

It is now 180.48 so is this sell or buy? can you guess?

Investor paid 180 per share and sell to maker 181 so they have profit 1p per share? it sound strange as nobody doing that as there are a lot sell at lose to run away.

If Vlad is trusted whe he promise somrthing that will never come.

On 2022 he public a RNS promise take blood sample from Covid patient then with advance research for quickly finding a treatment at that time using human mouse mode. until now research onle come out with CRB nothign left and nobody know what it does. Yes the way he treated market with that RNS and lend on place share at 7 p the peoples will know that what he done.

All RNSs still avaiables and you can check bacvk what promise from CEO.

In UK we have a Labour MP who said tax weath peoples more to help paying benifits, What is strange as she didnt think why dont ask Labour begging class citizens stop claim benifit and looking to lean a new job insteard of destroy and rob weath peoples. This is become Muslim conutry and only finding the way to take away everythign they can from investors.

What does FCA do to many AIMs company CEOs who rob market with many lie? FCA didn't do anythign but let it off and invetors lose money. but they introduced some complicated regulations to destroy market then what next. Whole market will collap as it is now a lot company run away from LSE .

sooner or later UK market will be nothing left .

The main point in this company is how they manage cash and spending base on CEO. For example what value does it return when THG buy a hotels and keep it running ? Is this sound strange itnt it's. Every years they invested multi millions into online platforms with never return but only cost all money on . That is why this lost making money but in fact two division are great generated profits.

The stuck as CEO is landlord of building and he set price for THG rent that without market competition then now he owe 50 % online platform and sign contact to tie THG must use that without open market competition. That are conflict of interest and only him play and setting and controls . That cost shareholders money.

Now it time to remove him and cut all off connection and can play with open market then this will change a lot if big shareholders can bring this evil CEO off .

5 billions value and now it worh over 400 millionsso that why peoples hate CEO as only him got benefit from public company . It is daily lights robber and it is only time sooner or later CEO must go. It cant be like this forever.

They need fund to keep it working. That is main issue in this time for company,As now nobody sure it work or not but they need money for 6 months to get the fisrt batch of data so that is why peoples scare to pour more money as only 2 months this share lose over 60 % .

All peoples in here have nothing to say about CAR T as we don't have enough knowledge but only mention about fund for company work.

It is only good if some big pharmaceutical come on broad and supportive buy more share or co op so they dont need to place share after this one. Until they can find new fund this share will be hanging around like this or maybe down as that is the road it go.

It mean many time when rns landed in the end of the day it close red. We don't know how today close but now show on Google 180 not a deal.